Dec 9 (Reuters) - Relmada Therapeutics ( RLMD ) said on
Monday it would discontinue the two late-stage studies planned
for the development of its depression drug and explore strategic
alternatives including a sale.
(Reporting by Christy Santhosh in Bengaluru; Editing by Sriraj
Kalluvila)